News

The International Society for Heart and Lung Transplantation (ISHLT) awarded grants to three researchers its 2022 Annual Meeting. ISHLT grants fund research to improve the care of patients with advanced heart and lung disease through transplantation, mechanical circulatory support (MCS), and innovative therapies.

The International Society for Heart and Lung Transplantation (ISHLT) will follow the xenotransplantation presentation from its Annual Meeting opening plenary session with an in-depth xenotransplantation webinar, 25 May at noon EDT on ISHLTv, the online education platform for the international heart and lung transplantation community.

During its 42nd Annual Meeting in Boston, the International Society of Heart and Lung Transplantation honored the recipient of the 2022 Lifetime Achievement Award, Hannah Valantine, MD, FRCP, MBBS.

ISHLT has established a new sister organization: the ISHLT Foundation. This new entity serves as the charitable arm of ISHLT, and will fund a global portfolio of research grants and fellowship awards to improve patient care for advanced heart and lung disease.

ISHLT has announced the results of the 2022 member elections for Professional Community leaders, who serve as representatives to the four ISHLT Interdisciplinary Network Steering Committees. Seventeen leaders across seven professional specialties were elected to serve three-year terms beginning 1 May, 2022, immediately following the 2022 ISHLT Annual Meeting.

The International Society for Heart and Lung Transplantation (ISHLT) will host its 42nd Annual Meeting and Scientific Sessions on 27-30 April, 2022. Attendees will meet in Boston, MA USA, marking the first time the ISHLT community has met in person since 2019.

Two International Society for Heart and Lung Transplantation (ISHLT) Academies will be held on 26 April in Boston, the day before the 42nd Annual Meeting & Scientific Sessions, 27-30 April.

ISHLT will host its 42nd Annual Meeting and Scientific Sessions on 27-30 April, 2022. Attendees will meet in-person in Boston, MA USA, and the event will include educational content spanning the breadth of clinical practice and research concerning heart and lung transplantation, advanced heart and lung disease, mechanical circulatory support, and pulmonary vascular disease. Virtual access to selected education will also be available.

ISHLT has announced the results of the member election for the 2022 Board of Directors. The Society will welcome six members of the Board of Directors at the 42nd Annual ISHLT Annual Meeting & Scientific Sessions on 27-30 April, 2022.

ISHLT will host its 42nd Annual Meeting & Scientific Sessions on 27-30 April, 2022 in Boston, MA USA. The preliminary program for the meeting is now available to browse at ishlt.org/ishlt2022, and currently features three plenary sessions, 18 sunrise symposia, and 35 invited symposia sessions.

ISHLT is now accepting applications for two research grants to be awarded in 2022, both funding research in mechanical circulatory support. Applications for the ISHLT/O.H. Frazier Award and the ISHLT/ICCAC VAD Coordinator Award will be accepted from now through 31 January, 2022.

ISHLT Academies have returned. The ISHLT Academies are standalone educational courses designed to improve and maintain the highest possible standards in the care of patients with advanced heart and lung disease. While the 2021 Academies were not able to be held face-to-face, the ISHLT has released its Core Competencies course in Pulmonary Hypertension with an online, self-paced curriculum.

The International Society for Heart and Lung Transplantation (ISHLT) has opened abstract submissions for its 42nd Annual Meeting & Scientific Sessions on 27-30 April, 2022. This event will include in-person and virtual elements and feature educational content spanning the breadth of clinical practice and research concerning heart and lung transplantation, advanced heart and lung disease, mechanical circulatory support, and pulmonary vascular disease.

ISHLT has announced the winners of the new ISHLT Professional Community Awards for Excellence. These awards recognize professional excellence in each of the Professional Communities represented within ISHLT, support the component groups that enable ISHLT’s interdisciplinary approach, and elevate and empower all Professional Communities equally.

As a Society committed to supporting and developing advanced heart and lung research—and to promoting the best work of the next generation of researchers—the International Society for Heart and Lung Transplantation gives three abstract awards each year to recognize high quality research from trainees, residents, fellows, and graduate students.

For the seventh year in a row, the Journal of Heart and Lung Transplantation’s Impact Factor earned the publication the number one ranking in the transplantation category. The Journal has also ranked number three in Surgery (from four in 2020), number five in Respiratory (from seven in 2020), and maintained its rank of number 13 in the highly competitive Cardiovascular category.

Evidence is emerging about the immunogenicity of vaccination to the SARS-CoV-2 virus in immune-suppressed individuals, including organ transplant recipients. The Journal of Heart and Lung Transplantation (JHLT) presents two key studies in thoracic organ transplantation.

The International Society of Heart and Lung Transplantation (ISHLT) awarded three grants to researchers in the fields of heart transplantation, MCS, and VAD coordination at the closing plenary session of its Annual Meeting on Wednesday, 28 April 2021.

During its 2021 virtual Annual Meeting, the International Society of Heart and Lung Transplantation (ISHLT) honored the recipients of its 2020 and 2021 Lifetime Achievement Awards, and announced the creation of the Amanda W. Rowe Distinguished Service Award.

ISHLT will host its 41st Annual Meeting & Scientific Sessions on 24-28 April, 2021. The all-virtual event will include educational content spanning the breadth of clinical practice and research concerning heart and lung transplantation, advanced heart and lung disease, mechanical circulatory support, and pulmonary vascular disease.